Eli Lilly reported financial results and guidance that outperformed expectations, driven by robust sales of tirzepatide products (Mounjaro/Zepbound), and sent its stock sharply higher. Lilly forecast strong growth for 2026, reflecting continued demand for its obesity and diabetes franchise and investor confidence in its commercialization trajectory. By contrast, Novo Nordisk warned of a substantial sales decline for 2026, citing pricing pressure and competitive dynamics despite a strong start to the oral Wegovy launch. The divergence underscores how market share, pricing agreements, and new oral formulations are reshaping competitive positions among GLP‑1 leaders.